Skip to main content
OpenTrials
Completed

NCT Number: NCT04350736

First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19

This is a phase 1 study in healthy subjects to evaluate the safety, tolerability and pharmacokinetics of single (Part A and B) and multiple (Part B) doses of inhaled TD-0903.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at Screening and weighs at least 50 kg.
  • Medically healthy with no clinically significant medical history, physical examination, spirometry, vital signs or ECGs.
  • Forced expiratory volume in 1 second (FEV1) ≥80%.
  • No clinically significant abnormalities in the results of laboratory evaluations.
  • Female subjects must be either of non-childbearing potential or if of childbearing potential, subject must not be pregnant or breastfeeding, and must agree to use a highly effective birth control method.
  • Male subjects must agree to use condoms, in addition to the use of highly effective pregnancy prevention measures with female partners of childbearing potential.
  • Understands the correct technique for the use the nebulizer device(s).
  • Other inclusion criteria apply

Exclusion criteria

  • History or presence of clinically significant medical or psychiatric condition.
  • Abnormal ECG measurements at Screening.
  • Any signs of respiratory tract infection within 6 weeks of Screening.
  • Subject who has a current bacterial, parasitic, fungal, or viral infection; any infection requiring hospitalization or intravenous antibiotics within 6 months prior to Screening.
  • Positive test for SARS-CoV-2
  • Subject has any condition of the oro-laryngeal or respiratory tract.
  • Uses or has used tobacco or nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, patches etc.) within 6 months prior to screening
  • Additional exclusion criteria apply

Treatment and study plan

TD-0903

Drug

Study drug to be administered by inhalation

Placebo

Drug

Placebo to be administered by inhalation

Primary outcomes

  1. Safety and Tolerability of SAD of TD-0903: Adverse Events

    Time frame: Day 1 to Day 8

    Number and severity of treatment emergent adverse events

  2. Safety and Tolerability of MAD of TD-0903: Adverse Events

    Time frame: Day 1 to Day 14

    Number and severity of treatment emergent adverse events

Secondary outcomes

  1. Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): AUC

    Time frame: Day 1 through Day 4

    Multiple PK variables of TD-0903 will be assessed during SAD and may include, but are not limited to: Area under the plasma concentration-time curve (AUC)

  2. Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Cmax

    Time frame: Day 1 through Day 4

    Multiple PK variables of TD-0903 will be assessed during SAD and may include, but are not limited to: Maximum observed concentration (Cmax)

  3. Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Tmax

    Time frame: Day 1 through Day 4

    Multiple PK variables of TD-0903 will be assessed during SAD and may include, but are not limited to: Time to reach maximum observed concentration (Tmax)

  4. Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): AUC

    Time frame: Day 1 through Day 9

    Multiple PK variables of TD-0903 will be assessed during MAD and may include, but are not limited to: Area under the plasma concentration-time curve (AUC)

  5. Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Cmax

    Time frame: Day 1 through Day 9

    Multiple PK variables of TD-0903 will be assessed during MAD and may include, but are not limited to: Maximum observed concentration (Cmax)

  6. Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Tmax

    Time frame: Day 1 through Day 9

    Multiple PK variables of TD-0903 will be assessed during MAD and may include, but are not limited to: Time to reach maximum observed concentration (Tmax)

Sponsors and collaborators

Lead sponsor

Theravance Biopharma

Industry

Registry information

Official study title

A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Apr 17, 2020
Registry last updated
Jul 1, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.